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INTRODUCTION 
Discoid lupus Erythematosus (DLE) is a chronic disfiguring 
inflammatory skin disease. It is the most common form of cutaneous 
lupus erythematosus. It is characterized by erythematous indurated well 
defined scaly plaques of variable size, that resolve with atrophy, scarring 
and pigmentary changes. Follicular involvement is a prominent feature in 
DLE. Since there are only few published studies on DLE reported from 
India, a complete clinical profile of DLE patients was studied here. 
Lupus Erythematosus (LE) is a multisystem autoimmune disorder. 
Professor James Gilliam classified cutaneous lesions of LE as specific 
and non-specific based on the characteristic histological changes. 
The word ‗lupus‘ means ‗wolf‘ in Latin reminding the destructive 
injuries in the disease to the bite of the animal. 
Cutaneous involvement is the second common clinical 
manifestation in LE next to joints. Among the LE specific skin lesions, 
DLE rarely manifests with systemic disease. Although discoid cutaneous 
lesions are typical of DLE, they are also seen in as many as 14% of the 
patients with systemic lupus erythematosus (SLE). 
  
 
DLE is worldwide in distribution affecting frequently black people. 
The disease has a characteristic age and sex pattern, affecting individuals 
between 20-40 years of age with female preponderance. 
The etio-pathogenesis of cutaneous lupus erythematosus (CLE) is 
thought to be related to the same autoimmune abnormality responsible for 
the systemic components of LE. The key feature in the pathogenesis is up 
regulation of the interferon-α (IFN-α) signaling. 
Depending on the extent of the lesion involvement, DLE is 
classified as localized and disseminated type. 
DLE lesions show characteristic histological features. 
Characteristic staining patterns are observed in the serological ANA-IFA 
testing and in the immunofluorescence study of the lesion.  
Treatment options are based on the extent and severity of the 
disease. Sun-protection was advised for all patients and is advised to wear 
a broad-brimmed hat, protective clothes and to avoid short-sleeved shirts. 
Frequent sunscreen application, potent topical steroids, oral antimalarials, 
oral prednisolone are found to be useful.  
 
 
  
 
REVIEW OF LITERATURE 
HISTORICAL ASPECTS 
 Laurent Theodore Biett of Paris first described Lupus 
Erythematosus as Erythema centrifugum and was reported by his 
student Cazenave in 1833
[1].
 
 Biett‘s student Pierre Louis Alphee Cazenave renamed erythema 
centrifugum and coined the term Lupus Erythematosus in 1851
[1, 2].
 
 In 1866, Ferdinand Von Hebra used the metaphor of a butterfly to 
describe malar rash 
[3].
 
 In 1872, Moriz Kaposi first described the systemic features of the 
disorder. 
 In 1872, Kaposi described the exclusively cutaneous form of the 
disease as discoidal lupus 
[1].
 
 Sir William Osler coined the term systemic lupus erythematosus. 
 Jonathan Hutchinson described the photosensitive nature. 
 In 1948, Hematologist Malcolm Hargraves discovered the LE     
cell 
[4].
 
 In 1958, George Friou, demonstrated Anti nuclear factor [5]. 
  
 
 In 1955, Moore ad Lutz described the phenomenon of biological 
false positive VDRL in Lupus patients. 
 Leonardt, Arnett and Schulman described familial aggregation of 
lupus 
[6].
 
 In 1954, Drug induced lupus was first described. 
 In 1894 Payne first reported the use of quinine in the treatment of 
lupus erythematosus 
[7].
 
 In 1951, quinacrine was the first antimalarial to be used in the 
treatment of DLE. 
 
 
 
 
 
 
 
  
 
EPIDEMIOLOGY OF DISCOID LUPUS 
ERYTHEMATOSUS (DLE) 
INCIDENCE 
 The exact incidence and prevalence of DLE are unknown; DLE is 
responsible for 50 – 85% of cutaneous lupus erythematosus. Incidence of 
cutaneous LE is equal to that of SLE.
 [8] 
The incidence of DLE in one 
study was 3.56 per 100 000 persons: 1.04 per 100 000 for the generalized 
form and 2.52 per 100 000 for the localized form 
[8]
 
AGE 
 DLE is most common in individuals between 20 and 40 years of 
age. 
[9]
 But it can occur at any age. Cases have been reported in less than 
15 years of age and in elderly over 70 years of age. 
[10]
 
SEX 
 DLE has a female preponderance. Female to male sex ratio was 
found to be 3: 2 to 3: 1. 
[9]
 Age of onset was slightly later in males when 
compared to females 
[11]
 
  
 
RACE 
All races are affected. But the prevalence rate was higher in black 
race (African Americans) 
[9]
 
ETIO – PATHOGENESIS OF DLE 
 The pathogenesis of LE-specific skin lesion is inextricably 
intertwined with SLE pathogenesis. 
[9]
 Etio - pathogenesis is believed to 
be due to the interaction between genetic, environmental and retroviral 
factors resulting in loss of self tolerance. 
Susceptibility Phase 
[9]
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SUSCEPTIBLE GENES 
Genes of class I encode HLA A, B, Cw, those of class II encode 
HLA DP, DQ, DR, and those of class III encode molecules like 
components of complement C4A,B, C2, TNF, and heat shock proteins, 
(HSP)
[13]
 
HLA Associations: 
1. HLA Association in DLE shows increased susceptibility with 
HLA-B7,-B8 among class I MHC. HLA-DR2, -DR3, -DQA0102 
among class II MHC 
[9]
 
Other haplotypes with increased susceptibility to DLE are A
*
03, 
B
*
07, DRB1
*
15 
[12]
 
Complement deficiencies: 
2. Inherited deficiencies of C2 & C4 complement components have 
been strongly linked to DLE. There is partial deficiency of both C4 
allotypes in lupus panniculitis. 
[13]
 These complement deficiencies may 
cause failure to clear immune complexes and apoptotic cells. Increased 
numbers of apoptotic cells due to increased formation or reduced 
clearance, in turn lead to immunologic stimulation and finally to 
increased anti-Ro formation 
[13]
 
  
 
TNF genes and Heat shock proteins genes: 
3. TNF genes & heat shock proteins genes that belong to class III 
MHC exacerbates cutaneous lupus erythematosus after UV radiation 
exposure, the pathogenic mechanism being translocation of intracellular 
and intranuclear antigens and their exposure to the immune system. 
[14]
  
Familial cases of DLE were found in 4% in one series. 
[15]
 
Genes outside MHC: 
4. Genes outside MHC that could be associated with the susceptibility 
to cutaneous LE lesions are : 
a) Genes encoding cytokines (IL-1, IL-10) and their receptors (Fc 
RII, TCR), 
 b) Adhesion molecules (ICAM-1, E-Selectin), 
 c) Antioxidant enzymes (GST-Ml) and  
d) Apoptosis genes (fas). 
[13]
 
Human Endogenous Retroviruses: 
HERVs (Human Endogenous Retroviruses) that have originated 
from exogenous retrovirus, have integrated in to genome. 
[13]
 They are 
  
 
transmitted genetically and are replication defective. 
[13]
 HERVs can lead 
to auto immunity directly by encoding auto antigens, or indirectly by 
affecting the expression of gene-regulating immune responses and 
tolerance. 
[16]
 
Induction phase (or) induction by environmental factors 
Ultraviolet Radiation 
UV radiation (both UVA and UVB) is the most important inducing 
factor of systemic manifestation of LE and LE specific skin disease. 
1. UV radiation induce apoptosis of keratinocytes there by 
making cryptic peptides available for immunosurveillance
[17]
 (i.e.) it 
results in translocation of nuclear antigens Ro, La, and calreticulin, from 
its normal locations inside epidermal keratinocytes to the cell surface.
[17]
 
2. UVB radiation induces release of CCL27 (cutaneous T cell -
attracting chemokine) which up regulate expression of chemokine that in 
turn activate auto reactive T cells & IFN-  producing Dendritic cells.
[18]
 
Drugs 
Drugs induce lupus erythematosus by the following mechanisms. 
1. Drugs that produce hypomethylation of DNA in turn will increase 
the activity of auto reactive lymphocytes.
[9]
 
  
 
2. Photosensitizing drugs like UV radiation induce apoptosis of 
keratinocytes, translocation of nuclear antigens resulting in 
enhanced production of proinflammatory cytokines like TNF- , 
IFN-  
[19]
  
 Drugs that induce DLE lesions are isoniazid, D-penicillamine, and 
griseofulvin. 
[20] [21] [22] 
Positive ANA, musculoskeletal symptoms and serositis are the 
predominant clinical presentation in drug induced LE 
[153]
 25% of 
hydralazine induced and less than 5% of procinamide induced LE 
patients showed features of skin changes 
[153]
 Anti histone auto 
antibody represent the serologic marker in drug induced LE/ANA
[153] 
Drugs like hydrochlorothiazide, diltiazem, griseofulvin, terbinafine 
induce subacute cutaneous lupus erythematosus (SCLE) lesions and 
anti-Ro auto antibody. 
[153]
 
Anti TNF- inhibitor induced lupus have skin manifestations 
including malar rash, SCLE, DLE, photosensitivity and purpura. 
[152] 
ANA and anti-ds DNA are predominant antibodies and not anti 
histone antibodies with the TNF-  blockers. 
[151]
 
 
  
 
Viruses 
 The antibodies to reovirus RNA found in 42% of patients suggest 
that viruses may have a pathogenic role in DLE. 
[20]
 DLE occurring at 
small pox vaccination scar 
[23]
 and herpes zoster scar 
[24] 
speculate the role 
of viruses as inducing factor in CLE. 
 Epstein – Barr virus (EBV) induces SLE by the following 
mechanisms  
1) Molecular mimicry 
[25]
 
 2) Through aberrant activation of TLR-7
[26] 
and  
3) By impaired EBV-specific T-cell response and increased levels of 
EBV-directed antibodies 
[27]
 
Tobacco Exposure 
 Lipogenic aromatic amines in tobacco smoke suggest increased 
frequency of DLE in smokers. 
[9]
 Smoking also has an impact on 
management. Smokers are less responsive to antimalarial          
treatment.
[28] [29] [30] 
 
 
  
 
Antigen Processing Dendritic cells 
Dendritic cells are monocyte derived cell; exist as myeloid 
dendritic cell and plasmacytoid dendritic cell. 
In normal individuals, in the absence of inflammation, the 
immature dendritic cells act as housekeepers and maintain peripheral 
tolerance to self antigens. 
[9]
 
 In the background of genetic susceptibility and inducing factors 
like microbial exposure and inflammation, apoptosis occurs. The self 
antigens exposed after apoptosis are presented by mature dendritic cell to 
naive T cell in draining lymph node resulting in T cell & B cell activation 
with subsequent launching of an adaptive immune response.
[31]
 
 Plasmacytoid dendritic cell in lymphoid organs, on exposure to 
viral and bacterial pathogens produce IFN- . Elevated IFN scores were 
reported in DLE and SCLE 
[32]
 that confirms the pathogenetic role of 
IFN- . IFN-  activate myeloid dendritic cell to capture circulating 
apoptotic cells and present self-antigens to auto reactive CD4 T cells and 
also support B-cell proliferation and differentiation, leading to the clinical 
expression of LE.
 [33]  
 
  
 
Role of complement: 
Normally, complement proteins bind to apoptotic cells, which are 
then disposed of by ―housekeeping‖ macrophages. [9] High risk for SLE is 
conferred by homozygous deficiencies of early complement components 
or their inhibitors, including C2 and C4 within the HLA gene complex 
and non-HLA C1q, 1r and C1-INH. 
[34] [35] [36][37]
 When complement 
proteins are deficient (a common characteristic of patients with lupus) 
and when they are not present on apoptotic cells, the apoptotic cells are 
recognized by dendritic cells (DCs) that are able to stimulate the adaptive 
immune response 
[9]
 
Role of inflammatory cytokines 
1. Central to the pathogenesis is up regulation of the interferon-α 
(IFN-α) signaling. [38] 
2.
 Up regulation of IFN – inducible antiviral protein Myxovirus–     
A. 
[38] 
3. TNF-  produced by keratinocytes on exposure to UV radiation 
a) Induce apoptosis 
b) Release proinflammatory cytokines through NF-  and 
  
 
c) Stimulates adaptive immune response by inducing HLA-DR 
expression. 
[9]
 
Both TNF- and Anti-TNF therapies like etanarcept and 
infliximab results in the development or worsening of LE. TNF-
regulates IFN-  production in vitro by inhibiting the generation 
plasmacytoid DCs. 
[39]
 Thus over expression of IFN-α is thought to be a 
key event in immune dysregulation in lupus. 
[9]
 
4. Strong expression of TNF-related apoptosis-inducing ligand 
(TRAIL) in skin and blood. 
[41]
 
5. Interleukin (IL)-18 and the over expression of IL-18 receptor in 
keratinocytes was found to induce the apoptosis of keratinocytes via 
increased tumor necrosis factor (TNF)-α and decreased IL-12 
production 
[40] 
 
6. Some CLE patients showed increased IL-17 levels 
[40] 
7. Down regulation of TGF- , IL – 10 was observed  in DLE      
patients 
[42]
 
Role of Toll like Receptors (TLRs) 
 Stimulation of TLRs by circulating DNA, anti DNA complexes 
induces proliferation of auto reactive B cells and IFN-  production by 
  
 
dendritic cells. 
[9]
 Members in the TLR7/TLR8/TLR9 activation pathways 
are candidate genes for increased risk of the generation of auto antibodies 
to nuclear complexes that are found in SLE patients 
[43]
 
 Thus blocking TLRs may have therapeutic implications in lupus. 
[9]
 
Expansion and Injury phase 
T Cells 
 T cells mediating a key role in induction and expansion phases are 
involved in both central and peripheral tolerance.
[9]
 
 Self antigen presentation by DCs to auto reactive T cells leads to T 
cell activation which in turn activates auto reactive B cells to produce 
auto antibodies. 
A pan -T cell dysfunction seems to exist in SLE, which is 
characterized by exaggerated helper and diminished regulatory / 
suppressor CD4+CD25+ and CD8+ T cell activities.
[44]
 Cytotoxic T 
lymphocytes mediate tissue damage in SLE and in the injury phase of 
CLE.
[9]
 
 Increased number of skin homing cytotoxic T lymphocytes 
associated with expression of IFN-  inducible protein MXA results in 
scarring skin lesions of DLE.
[45]
 
  
 
B Cells 
 The production by B cells of auto antibodies against nuclear 
antigens is the hallmark of SLE.
[46] 
 These auto antibodies form immune complexes and induce tissue 
damage in LE.
[9]
 
 B cells may not be important in CLE which is supported by the 
suggestion that anti B cell therapies (Rituximab) are less effective for 
CLE.
[9]
 
Clinical Features 
 The classical DLE lesion begins as red purple macules, papules or 
small plaques and subsequently develops a hyperkeratotic surface. Early 
classic DLE lesions typically evolve in to well defined, sharply 
demarcated erythematous discoid plaques covered by an adherent scale 
that extends in to the orifices of dilated hair follicles.
[9]
 
 Discoid plaques vary in size from a few millimeters to 10 – 
15cm.
[11]
 
 When the adherent scales are removed, the undersurface shows 
horny plugs that have occupied dilated pilosebaceous canals. This is 
called carpet tack (or) tin tack sign (or) cat‘s tongue sign.[47] The carpet 
  
 
tack sign is also seen in localized pemphigus foliaceus
[48]
 and in 
seborrhoeic dermatitis. DLE lesions typically expand with erythema and 
hyper pigmentation at the periphery.
[9]
 Lesions spread centrifugally and 
merge. Resolution of lesions results in atrophy and scarring with 
pigmentary changes. In Asian Indians the disease may present as macular 
hyper pigmentation.
[9]
 
Wide follicular pits containing blackheads or scale occur mainly in 
the concha or triangular fossa of the ear termed Shuster‘s sign; occur in 
up to 1/3
rd
 of cases of DLE.
[49] 
But they also occur in SLE. 
Localized cribriform scarring occurs mostly on the face.
[11]
 
Localized DLE (LDLE) 
 Localized DLE indicates only the head and neck involvement 
affected.
[50]
 Face is most commonly affected.
[51]
 Scalp, ears, nose, arms, 
legs and trunk are affected to a lesser extent.
[11] 
 The lesions may be bilateral (not necessarily be symmetrical) or 
unilateral.
[11]
 
Disseminated DLE (DDLE) 
 Characteristic lesions of DLE that occur in a widespread pattern on 
the trunk and limbs are termed as disseminated (or) widespread DLE.
[11]
 
  
 
The appearance may be indistinguishable from the papulo-squamous type 
of SCLE, but scarring occurs in most patients,
[11]
 in contrast to SCLE 
lesions that are non-scarring.
[52]
 Distribution of lesions may occur in a 
wide spread pattern on the trunk and limbs.
[11] 
Lesions on the dorsa of the 
hands, palms or toes occurred in 6% of patients.
[11]
 
 Disseminated lesion with reticulate telangiectasia was described. 
This type of telangiectasia is possibly similar to ‗lupus erythematosus 
telangiectoides‘, first described by Crocker. 
[53]
 
 Other variants encountered in disseminated DLE are annular, 
bullous 
[54], linear (following Blaschko‘s lines) [55] and arteritic lesions 
have been reported.
[11] 
Annular variant of DDLE has been called lupus 
erythematosus gyratus repens.
[11] 
Variants of Discoid Lupus Erythematosus 
 Hypertrophic (or) Verrucous DLE, Lupus panniculitis with DLE, 
Tumid LE, Chilblain lupus, Mucosal DLE, Lichenoid DLE (LE / LP 
overlap, lupus planus)
[9] 
were the variants of DLE. 
 Hypertrophic (or) Verrucous DLE 
 Hypertrophic DLE was first described by Behcet as Lupus 
erythematosus hypertrophicus et profundus in 1940.
[56] [57] 
Verrucous 
  
 
lesions with raised, indurated edges are most frequently reported on 
extensor aspect of the forearms, face and upper trunk.
[58]
 Other sites 
where warty lesions are most commonly seen are nose, temples, ears and 
scalp. Difficulty in walking is associated with lesions on palms and 
soles.
[11] 
 Hyperkeratotic papulonodular lesions resembling keratoacanthoma, 
hypertrophic lichen planus
[59]
 or nodular prurigo also occurs in verrucous 
DLE. Usually hypertrophic DLE patients have classic DLE lesions 
elsewhere in the body.
[60]
 
 The lesions are characterized by dull, red indurated unique or 
multiple papulonodular lesions covered with keratotic scale or as larger 
plaques covered by an adherent multilayered ostraceous horny white or 
yellowish material or as regionally diffuse hyperkeratosis that resemble 
as chalky dust applied over the skin.
[61]
 Hypertrophic DLE rarely 
develops to  systemic lupus erythematosus. 
Lupus Panniculitis 
 Lupus panniculitis has been referred as Kaposi – Irgang disease 
(or) Lupus erythematosus profundus.
[9] 
It can occur at any age and has 
been reported in childhood.
[62]
 They are firm, rubbery, sharply defined, 
persistent nodular lesions of varying sizes.
[11] 
Classical lesions of DLE 
  
 
may be found elsewhere. The lesions of lupus panniculitis heal with 
depressed areas or anetoderma.
[11]
 Dystrophic calcification and 
ulcerations occur in older lesions.
[9] [61]
  
  Breast nodules in LE panniculitis has been called lupus mastitis 
and may herald SLE. 
[63]
 Most lesions are usually found in areas of 
increased fat deposition such as the trunk, buttocks, proximal upper and 
lower extremities, but the shoulders and thighs are further sites of 
predominant involvement. 
[61]
 Lesions may also develop on scalp, parotid 
region and periorbital tissues. 
[61] [64] [65]
 
 LEP can be found in approximately 2-10% of patients with SLE.
[61]
 
Roughly 50 percent of patients with LE profundus/panniculitis have 
evidence of SLE. 
[11]
 
 Some have used the term LE profundus to designate those patients 
who have both LE panniculitis and DLE lesions and LE panniculitis to 
refer to those having only subcutaneous involvement.
[11]
 
Tumid Lupus Erythematosus (LET) 
 Tumid LE is a rare subtype of chronic cutaneous lupus 
erythematosus that was first described by Gougerot and Bournier in 
1930.
[66]
 LET is characterized clinically by erythematous, edematous, 
succulent, non scarring plaques in sun exposed regions. 
[67]
 
  
 
 In a study of 40 patients of LET 70% of the patients showed a 
remarkable photo sensitivity and complete resolution of skin lesions with 
antimalarial therapy. 
[67] [68]
 In about 10% of the patients, ANA were 
detected. There was no evidence of underlying systemic involvement in 
any of the patients. 
[67] [68]
 Tumid lesions have tendency to recur.
[68]
 The 
main differential diagnoses are polymorphic light eruption, Jessner‘s 
lymphocytic infiltration of the skin, reticular erythematosus mucinosis 
and pseudo lymphoma. 
[67]
 
 Chilblain lupus Erythematosus / perniotic LE: 
Chilblain LE is seen commonly in women 
[69]
 the lesions result 
from micro vascular injury secondary to cold exposure and due to hyper 
viscosity from immunological abnormalities.
[69]
 Clinically the lesions 
develop on the toes, fingers and face as purple-red patches, papules and 
plaques. As they evolve, assume the appearance of scarred atrophic 
plaque with telangiectasia.
[9] 
Ulceration is common in digital pulp lesions 
and sole lesions go in for necrosis easily.
[70]
 Anti–Ro/SS-A antibodies are 
the auto antibodies encountered in chilblain lesions.
[71] 
Persistence of 
lesions beyond the cold months, a positive ANA or presence of one of the 
ACR (American college of rheumatology) criteria for SLE helps to 
distinguish chilblain LE from idiopathic chilblains.
[72] 
  
 
 Nearly twenty percent of patients with chilblain LE later develop 
SLE.
[9] 
Mucosal DLE 
 Oral mucosa is most frequently affected.
[9] 
 The prevalence of mucous membrane involvement in chronic 
cutaneous LE is about 25%.
[9] 
Nasal, conjunctival and genital mucosal 
surfaces can also be affected.
[73] 
 With in the mouth, buccal mucosa is most commonly involved. 
Individual lesions begin as painless, erythematosus patches later mature 
in to chronic plaque having a sharply marginated irregularly scalloped 
white border with radiating white striae and telangiectasia in buccal 
mucosa.
[9]
 Plaques on palatal mucosa show hyperkeratotic white strands 
with encircling zones of punctate erythema giving a honeycomb 
appearance.
[73]
 Older lesions develop central depression and painful 
ulceration.
[73]
  
 Chronic DLE plaques appear on the vermillion border of the lips, 
involvement of the lips present as a diffuse cheilitis especially on the 
more sun exposed lower lip.
[9]
 
  
 
 Chronic mucosal DLE lesions can develop malignancy like 
squamous cell carcinoma.
[73]
 The prevalence of mucosal involvement in 
LE patients is debatable. Some authors suggest that the prevalence of oral 
lesion in SLE is about 9–45% where as it is about 3–20% in patients with 
Cutaneous lupus erythematosus. 
[74, 75, 76, 77]
 
LE/LP Overlap syndrome: 
Hypopigmented atrophic patches and plaques with livid red to 
bluish violet color showing telangiectasia and scaling on the surface
[154]
 is 
the clinical picture. These lesions are usually seen in the extremities. 
Classic lesions of both LP and discoid lupus erythematosus (DLE) 
are uncommon in LE/LP overlap but the morphology share features of 
both the disease.
[78]
  
Histopathology reveals a lichenoid infiltrate characteristic of LP 
and LE features in the same biopsy.
[80] 
Direct immunofluorescence (DIF) aids in diagnosis in 
histologically doubtful cases, revealing colloid bodies staining with IgG, 
IgM and C3 in the epidermis or at the dermoepidermal junction (DEJ) as 
seen in classic LP.
[81] 
Linear to granular deposits of IgM and C3 
suggesting LE are also visible in DIF rarely.  
  
 
Drugs found effective in this syndrome are oral retinoids, 
ciclosporin 
[82]
 and hydroxychloroquine 
[83] 
 
Progression of LE/LP syndrome to SLE is 5-10% 
[79]
 
Nail changes in DLE 
 Subungual hyperkeratosis is more common than the red-blue 
discoloration of the nail plate with longitudinal striae and crumbling away 
of the nail. 
[84] 
Eye lesions in DLE 
Lesions are more common on the lower eyelid, outer one third. 
Palpebral lesions without lesion elsewhere on the face have been 
reported. 
[85]
 
The different ocular manifestations and complications of DLE 
[86-94]
 
were 
Orbit -  Proptosis, Periorbital edema 
Eyelids - Chronic blepharitis, lashloss, scarring, destruction and 
disfigurement, ectropion, entropion, trichiasis, panniculitis, pigmentary 
changes 
Conjunctiva - Conjunctivitis, hypertrophic / verrucous lesion, 
scarring symblepharon  
  
 
Cornea  - Stromal keratitis 
Acute mucinosis of the eyelids and periorbital skin can occur.
 [95]
 
 Scarring Alopecia in DLE: 
The lymphocytic infiltrate in perifollicular region was more around 
the mid-follicle at the level of the sebaceous gland. 
[96]
 The changes 
observed were alteration in the expression of the matrix molecules, the 
proteoglycans in the connective tissue sheath and in the keratin 
intermediate filaments of the outer root sheath cells at the mid follicular 
level in normal and diseased scalp 
[96].
 Loss of stem cells in the bulge 
region plays a major role resulting in cicatricial alopecia in DLE lesions. 
[96] 
There was a marked reduction in sebaceous glands size in the diseased 
scalp. 
[96] 
34% of DLE patients expressed features of scarring alopecia 
[96] 
in a study by Wilson et al. 41.9% of all scarring alopecia were due to 
DLE. 
[97]
 
Associated conditions 
Small telangiectasia on face, dilated nail fold capillaries, mild 
diffuse alopecia, alopecia areata,
[98]
 bilateral parotid enlargement,
[99]
 
livedo reticularis on legs,
[100]
 Porphyria (cutanea tarda, variegate, acute 
intermittent, erythropoietic protoporphyria) Pemphigus, Myasthenia 
  
 
gravis, Thymoma, Chronic lymphocytic leukaemia, Macroglobulinaemia, 
Benign monoclonal gammopathy, Multiple myeloma, Polychondritis, 
Thyroiditis,
[101]
 Carpal tunnel syndrome, Polymorphic light 
eruption
[102,103,104] Sheehan‘s syndrome, vitiligo,[105] systemic sclerosis 
(scleroderma) 
[106]
 have been reported in association with DLE. 
Histopathology of Discoid Lupus Erythematosus 
 Discoid lesions show changes that may be apparent at all levels of 
the skin, but all need not be present in every case. 
[107]
 
Stratum Corneum: 
Hyperkeratosis with keratotic plugs found mainly in dilated 
follicular openings and in openings of eccrine ducts as well. 
[107]
 
Epithelium:  
The epithelium shows thinning and flattening of stratum 
malphighii and these changes vary with the clinical character of      
lesions. 
[107]
 
 Hydropic degeneration of basal layer is the most significant 
histological change. 
[107] 
  
 
 Basal keratinocytes show individual cell necrosis and 
squamatization. 
[107]
  
Basement Membrane:  
The basement membrane appears thickened and tortuous in long 
standing lesions correlating with deposition of immunoreactants. 
[107]
 
 With PAS stain, Basement membrane thickening becomes more 
apparent at dermal– epidermal interface, follicular – dermal junction [107] 
and in capillary walls.  
Stroma: 
The stroma shows a predominantly lymphocytic infiltrate admixed 
with plasma cells along the dermal-epidermal junction, around hair 
follicles and sebaceous glands. 
[107] 
The impinging infiltrate on 
pilosebaceous units leads to gradual atrophy and its disappearance. 
[107] 
 Patchy lymphocytic infiltrate in an interstitial pattern and around 
eccrine coils with extension into subcutaneous fat 
[107]
 may be present. 
Interstitial mucin deposition, dermal edema, vasodilatation and 
extravasations of erythrocytes, pigmentary incontinence and colloid 
bodies are seen in DLE lesions. 
[107] 
 
  
 
Mucin deposition (hyaluronic acid) is common in mid and lower 
dermis and is best demonstrated with colloidal iron (or) Alcian blue 
stains. 
[108]
 
Verrucous Lupus Erythematosus 
 Verrucous LE show two patterns histologically: 
 1. Epidermal hyperplasia with papillomatosis and surmounted by 
hyperkeratotic scale. Dyskeratotic keratinocytes with band like 
mononuclear cell infiltrate along the dermal – epidermal junction. [107] 
     2. Cup – shaped keratin filled crater surrounded by an acanthotic 
epidermis with elongated rete ridges and a sparse mononuclear infiltrate 
[107]
 with dermal changes similar to DLE. 
Lupus Erythematosus Profundus / Panniculitis 
LE Panniculitis is a mixed type of panniculitis 
[109]
 that reveal a 
deep lymphocytic infiltration in the fat lobules and in the septa. 
[110,111]
 
 Lymphoid aggregates (or) germinal (or) follicular centers are 
commonly seen. 
[110,111,109]
 
  
 
 Hyaline necrosis of fat is the distinctive feature where the fat cells 
having lost their nuclei show deposit of fibrin and other proteins in an 
eosinophilic matrix between residual fat cells. 
[110,111]
 
Calcification is a feature seen in older lesions. 
[111]
 
Lymphocytic infiltration of blood vessels is also seen in LE 
panniculitis. 
Tumid lupus Erythematosus 
Superficial and deep dermal perivascular, interstitial and 
periappendageal lymphocytic infiltrates with stromal mucin deposits. 
Epidermal changes are not observed in this type. 
[9,107] 
Focal interface 
changes at dermoepidermal junction and at follicular infundibula are 
observed in few studies. 
[112]
 
ANA in Discoid Lupus Erythematosus 
In the strict sense, antinuclear antibodies are auto antibodies 
directed against nuclear specificities, such as DNA or small nuclear 
ribonucleoproteins (snRNPs). 
[113]
 
With the advent of the fluorescent antinuclear antibody test 
(FANA), auto antigens through out the cell can be detected. Thus ANAs 
  
 
has expanded to include a diverse spectrum of nuclear and cytoplasmic 
specificities. 
[113] 
Thus ANAs have established collaboration between clinical 
immunology and molecular biology. 
[113] 
The evolution of the ANA technique range from the subjective (LE 
cell preparation) to immunofluorescence ANA (ANA – IFA) performed 
in a variety of substrates to the automated objective (ANA – EIA). [114] 
 The major development in ANA screening tests was the 
development of the indirect ANA – IFA in the 1950s. [114] 
 Thus the evolution from subjective to objective method, from 
manual to automated procedures provided the benefits like lowered costs 
for ANA tests and the potential for improving the consistency of 
performance of the ANA test by objective data. 
[114] 
Fluorescent anti nuclear antibody (FANA): 
FANA provides a rapid, yet highly sensitive screening method for 
ANA detection. Test sera at varying dilutions (typically serially 
increasing by twofold) are incubated with substrate cells, and bound 
antibodies are detected by fluorescein-conjugated anti–human IgG, 
followed by visualization via a fluorescence microscope. 
[115]
 Results 
  
 
typically are reported by two parameters—pattern and titer—with any 
pattern of reactivity at a titer of 1:40 or greater being considered    
positive. 
[115]
 
Enzyme Linked Immuno-Sorbent Assay (ELISA): 
ELISA provides highly sensitive and rapid technique for the 
detection of ANAs and determination of antibody specificity. 
[116]
 Test 
sera are incubated in wells precoated with purified target antigen; bound 
antibodies are detected via an enzyme conjugated anti-human 
immunoglobulin antibody, followed by color visualization with the 
appropriate enzyme substrate.
[116]
 This technique can denature auto 
antigens and can produce some false positive results which require further 
confirmation. Because of their ease of use, ELISAs continue to play a 
prominent clinical role. 
[116]
 
Target auto antigen and their ANA pattern in SLE: [116] 
Target auto antigens ANA Patterns 
dsDNA, ssDNA Rim, Homogenous 
Nucleosome structure Homogenous, Rim 
H1, H2A / B, H3, H4 Homogenous, Rim 
H3 Large speckles 
CENP-A, -B ,-C, -D Speckles 
  
 
Target auto antigens ANA Patterns 
PCNA Nuclear / nucleolar speckles 
Sm core B‘/B, D, E, F, G Speckled 
U1snRNP70K, A, C, U2snRNP, 
U5snRNP, U7snRNP, SR 
Speckled 
Ro ,La Speckled 
RNAPII Nuclear / nucleolar 
Ribosomal RNPs Nucleolar, cytoplasmic 
ANA positivity in DLE patients ranged from 2.7% to 68.5% in 
various studies. 
[117,118,119,120]
 
 ANA were commoner in older patients, in those who had suffered 
from the disease for longer periods or had more extensive skin 
involvement. 
[121]
 Regarding the pattern of ANA, the ‗homogeneous‘ type 
of antinuclear factor was reported twice as frequent as the ‗speckled‘ type 
in LE. 
Anti DNA antibodies- incidence varies from 0-27% 
[122,123,124]
 IgM 
antibodies to single strand DNA occur in one-fifth of patients and may 
indicate widespread, progressive disorder 
[123]
 
 Anti Ro antibodies in low titre are found in 10% of DLE 
[11] 
 
  
 
Direct immunofluorescence: 
Direct immunofluorescence has a significant value in the 
evaluation of patients with active cutaneous connective tissue disease. 
The intensity of the deposits of immunoreactants along the basement 
membrane in these patients correlates with the degree of 
interface/lichenoid dermatitis/ mucositis. 
[125] 
In discoid lupus erythematosus, the most common 
immunoreactants visualized with direct immunofluorescence is IgM. 
[125] 
Procedure 
A 4mm punch biopsy is taken from the lesion and non sun exposed 
uninvolved skin. For optimal results, an established lesion (present for 3 
months or longer) that has not been treated is submitted for study the 
specimen is washed with normal saline and sent in normal saline with in 
24 hrs. 
While processing, the specimen is washed several times in 
phosphate-buffered saline, snap frozen, sectioned, and incubated with 
fluorescein-conjugated antisera to IgA, IgM, IgG, and the third 
component of complement (C3) and then visualized under fluorescent 
microscope. 
  
 
In a positive test, there is continuous granular deposition of usually 
two or more immunoreactants (in a band) along the dermal-epidermal 
junction 
[107] 
.Variables that affect DIF results are the site of the biopsy 
(sun-exposed vs. sun-protected), duration of the lesion (acute, sub acute, 
chronic), disease activity and preceding therapy 
[107]
 .Lesions on the head, 
neck, and arms are positive more frequently (80 percent) than those on 
the trunk (20 percent) 
[9] 
DIF in DLE shows deposition of immunoreactants in specimen 
from sun exposed untreated lesions. The positivity in DLE lesion is more 
than 90% in untreated lesion and almost negativity in sun exposed 
uninvolved region. No deposition of immunoreactants in nonsunexposed 
uninvolved region in DLE.  
DIF in SLE shows deposition of immunoreactants in untreated 
lesion of sun exposed region, sun exposed uninvolved region and in 
nonsun exposed uninvolved region. The positivity is about 80 to 90% in 
untreated lesion, more than 80% in sun exposed uninvolved skin, more 
than 91% in nonsunexposed uninvolved skin in active SLE and 33% in 
nonsunexposed uninvolved skin in inactive SLE, this indicates renal 
involvement. Thus DIF in LE varies depending on the prior treatment, 
disease activity and the site of biopsy. 
  
 
The lupus band test, described as positive when granular IgG is 
present along the basement membrane zone in specimens from sun-
protected nonlesional areas and has been abandoned due to its 
unreliability and current availability of the other more reliable methods 
for early diagnosis and prediction of systemic disease in lupus 
erythematosus. 
[126]
 
LE Profundus: 
Immunoglobulin and complement deposits are usually found in 
blood vessel walls of the deep dermis and sub cutis 
[9]
. Immunoglobulin 
deposits at the dermal-epidermal junction may or may not be present, 
depending on the site of biopsy, the presence or absence of accompanying 
SLE, and the presence or absence of overlying changes of DLE at the 
dermal-epidermal junction. 
[9]
 
ARA criteria for SLE: 
According to revised ARA criteria 4 or more criteria out of 11 
should be present serially or simultaneously to establish the diagnosis of 
SLE. 
The muco cutaneous criteria included are photosensitivity, malar 
rash, discoid rash and painless oral or nasopharyngeal ulcers 
[9]
 
  
 
The systemic features in the criteria are rheumatologic 
manifestation in the form of arthritis, serositis, renal manifestation 
including persistent proteinuria or cellular casts, neurological features in 
the form of seizures or psychosis in the absence of underlying medication 
or metabolic derangements and hematological dysfunction including 
hemolytic anemia or leucopenia or lymphopaenia or thrombocytopenia 
[9]
. 
The immunological criteria include two features viz. the presence 
of high titre of anti-nuclear antibody and antibodies to naïve DNA or 
antibody to Sm nuclear antigen or antiphospholipid antibodies in the form 
of anti cardiolipin antibody, lupus anticoagulant or false positive 
serological test for syphilis persisting for more than 6 months. 
[9]
 
The Systemic Lupus International Collaborating Clinics (SLICC) 
group proposed revision and validation of the ARA criteria for SLE in 
2012. 
[131]
 
The SLICC classification system includes 11 clinical criteria and 6 
immunological criteria. 
[131]
 The additional validation in this criteria aside 
ARA criteria are inclusion of all types of LE-specific lesion and its 
variants and have included non-scarring alopecia as a separate criteria. 
[131]
 Importance is given for urine protein-creatinine value in renal 
pathology. Under neurological manifestation apart from seizures and 
  
 
psychosis they have included acute confusional state, mononeuritis 
multiplex, myelitis and peripheral or cranial neuropathy. 
[131] 
Low complement and direct coomb‘s test are included additionally 
in immunologic criteria in the SLICC classification system. 
[131] 
Four criteria of which a minimum of one clinical and one 
immunological criterion should be present or features of lupus nephritis 
in renal biopsy with ANA or antids - DNA should be there to establish 
the diagnosis of SLE 
[131]
 
The validated SLICC classification criteria are more consistent 
with emerging concepts of SLE pathogenesis when compared to revised 
ARA criteria. 
[131]
 
Neoplasm in DLE: 
Squamous cell and less frequently, basal cell carcinomas occur in 
the scars of DLE, particularly on the scalp, ears, lips and nose 
[127]
 
keratoacanthoma 
[128]
, malignant fibrous histiocytoma 
[129]
 and atypical 
fibroxanthoma 
[130]
 in DLE lesions have been reported. 
Squamous cell carcinoma arising in discoid lupus erythematosus 
lesion is rare; there are reports of SCC occurring on DLE lesions over 
scalp and upper lip. 
[134]
 
  
 
Most cases of SCC have been reported in sun-exposed region in 
whites. A case of squamous cell carcinoma arising in DLE scars in sun-
protected region has been reported. 
[132]
 
 Numerous squamous cell carcinomas in the scars resulting from 
discoid lupus 
[133]
 are also reported. 
Course of DLE and its association with SLE: 
Approximately 5 percent of patients presenting with isolated 
localized DLE subsequently develop SLE 
[9]
. The progression risk is more 
in patients with disseminated DLE (22%). 
[11]
 Well-defined discoid 
lesions with atrophic scarring, as seen in DLE, occur in about 15% of 
SLE patients 
[107]
. These DLE lesions may precede all other clinical 
features of SLE. Most of the SLE patients with preceding DLE will have 
a relatively benign course 
[119]
 
Risk factors for the progression of SLE in DLE patients:  
The presence of SCLE / ACLE skin lesions; diffuse non-scarring 
alopecia, LE-non-specific skin lesions such as vasculitis, periungual nail 
fold telangiectasia, Raynaud phenomenon; generalized lymphadenopathy 
clinically and unexplained anemia; marked leucopenia; false-positive 
tests for syphilis; hypergamma-globulinemia; an elevated erythrocyte 
  
 
sedimentation rate (especially > 50 mm/hour); persistently positive high-
titer ANA assay; anti-single stranded DNA antibody; positive, sun-
protected, non-lesional lupus band test (LBT) and high levels of soluble 
IL-2 receptor[9
]
 on investigation were the risk factors for progression to 
SLE. 
 
 
 
 
 
 
 
 
 
 
 
  
 
AIM OF THE STUDY 
1. To find out the clinical profile of discoid lupus erythematosus seen 
among patients attending the skin OPD. 
2. To find out the other dermatological and systemic associations in 
discoid lupus erythematosus patients. 
3. To study and correlate the various clinical parameters with both 
types of discoid lupus erythematosus and its morphological 
variants. 
 
 
 
 
 
        
 
  
 
MATERIALS AND METHODS 
The material for this study was from the patients attending the skin 
OPD, Government Rajaji Hospital, Madurai Medial College, Madurai 
during the period from October 2010 to September 2012. 
Inclusion criteria 
1. Patients clinically diagnosed to have discoid lupus erythematosus 
lesion and confirmed by histopathological examination. 
2. Clinically doubtful cases but confirmed by histology were 
included. 
Exclusion criteria 
1. Patients who did not give consent for biopsy were not subjected to 
biopsy procedure and were excluded. 
2. Patients who did not have clinico-pathological correlation were 
also excluded. 
A total of 51 patients clinically diagnosed to have discoid lupus 
erythematosus during this period were taken for the study. A detailed 
clinical history including the age at onset, duration, triggering factors, 
systemic symptoms, and family history were elicited. A complete general 
  
 
examination, systemic examination, dermatological examinations were 
made. Digital photographs were taken. 
The type, morphology and distribution of the skin lesions, the 
presence of other cutaneous and systemic associations were noted. 
Laboratory investigations included complete blood count, urinalysis, 
renal function test, erythrocyte sedimentation test (ESR) was done. 
Antinuclear antibodies (ANA) were detected using Hep-2 cells as 
substrate by immunofluorescence technique or by ELISA method in 30 
patients. 
Skin biopsy was done in all the patients after obtaining informed 
consent. After cleansing the area of the lesion chosen for biopsy with 
spirit, 2% lignocaine was infiltrated in to the area and tissue specimen 
was obtained by punch biopsy technique. The specimen were preserved 
in 10% formalin and submitted for histopathological examination to the 
department of Pathology, Madurai Medical College. 
Direct immuno fluorescence was done only for 5 patients due to 
financial constraints and patients were already on partial treatment during 
examination. The biopsies were taken from the lesion and also from non 
sun exposed uninvolved skin and preserved in normal saline and sent to 
the private laboratory for immunofluorescent study on the same day.       
  
 
OBSERVATIONS AND RESULTS 
A total of 51 patients with discoid lupus erythematosus who 
attended the out patient department in the department of Dermatology, 
Government Rajaji hospital, Madurai medical college, from October 2010 
to September 2012 were included in the study. Incidence in this study 
was 0.47 per 1000 cases among patients attending Dermatology clinic. 
The following observations were made. 
Table1: Clinical type of DLE 
Clinical type of DLE No. of patients Percentage (%) 
Localized 30 58.82 
Disseminated 21 41.17 
The localized type was found to be more common than 
disseminated type. 
  
 
Table 2: The age of onset 
Age of 
onset 
Localized Disseminated Total 
Percentage 
% 
0-10 - - - - 
11-20 - 2 2 3.9 
21-30 6 5 11 21.56 
31-40 11 8 19 37.25 
41-50 6 6 12 23.52 
51-60 5 - 5 9.8 
61-70 2 - 2 3.9 
 The majority of the patients (58%) had disease onset between 21-40years 
of age. 1 female patient with disseminated lesions had onset of the 
disease during her pregnancy. 
 
  
 
Table 3: Sex distribution 
Type of DLE Male Female 
Localized 3 27 
Disseminated 7 14 
Female to male ratio - 4.1: 1 
The female to male ratio in localized type is 9:1 and in 
disseminated type it is 2:1. Localized type was observed more common 
among female patients. Among male patients disseminated type was seen 
in higher proportion (7 of 10 i.e.70%) 
  
 
Table 4: Duration of the lesion 
Duration Localized Disseminated Total Percentage 
<1 year 14 7 21 41.17 
1-5 years 12 6 18 35.29 
5-10 years 2 3 5 9.8 
10-15 years 2 3 5 9.8 
15-20 years  2 2 3.9 
About 76% of patients had lesions less than 5 years of duration. 
19% of cases had disease for about five to fifteen years. Lesions beyond 
20 years were found in 2 patients (3.9%) with disseminated lesions. One 
among the 2 satisfied ARA criteria. 
 
 
 
 
 
  
 
Table 5: Triggering factors  
Inducing or trigger 
factor 
No. of 
patients 
Percentage % 
Occupation-
(excessive UV 
exposure) 
25 49.01 
Drugs 11 21.56 
Viral infection 2 3.9 
Trauma /burns 4 7.84 
Smoking 8 15.68 
Occupation related to excessive sun exposure was found in 25 
patients (49%). Prior history of drug intake was present in 11 patients 
(21%) such as anti tuberculosis drugs-isoniazid, anti hypertensive drugs, 
thyroxine and anti psychiatry drugs. History of preceding viral infection 
was elicited in 2 (3.9%) patients. Out of the total 10 male patients, 8 of 
them (15% of study group) i.e. 80 % were smokers. 
 
 
  
 
Table 6: Variants of DLE 
Variants Localized  Disseminated  Total  % 
Classical  16 5 21 41.17 
Classical,Mucosal  11 11 22 43.13 
Classical,Mucosal,verrucous - 2 2 3.9 
Classical,Mucosal,tumid 1 - 1 1.9 
Classical,Verrucous  - 1 1 1.9 
Classical,Panniculitis  - 1 1 1.9 
Verrucous  1 - 1 1.9 
Tumid  1 - 1 1.9 
Panniculitis  - 1 1 1.9 
 
 
 
 
  
 
Table 7: Variants of DLE 
Variant No.of patients Percentage 
Classical 48 94% 
Mucosal 25 49% 
Verrucous 4 7.8% 
Panniculitis 2 3.9% 
Tumid 2 3.9% 
Among the variants, classical DLE was seen in 94% of study group 
of which 28 patients were of localized type and 20 patients were of 
disseminated type. Mucosal manifestation was found in 25 patients 
(49%). Verrucous or hypertrophic DLE was seen in (7.8%) 3 male 
patients and in one female. Lupus panniculitis and tumid lesions were 
seen in 2 patients (3.9%) each respectively 
 
  
 
Distribution of lesion:  
Table 8 - HEAD and NECK involvement 
Site Localized Disseminated Total  % 
Scalp  11 15 26 50.98 
Forehead  3 10 13 25.49 
Eyelid  2 - 2 3.9 
Nose  11 4 15 29.41 
Cheek 11 9 20 39.21 
Ear  6 12 18 35.29 
Preauricular  3 - 3 5.8 
Perioral  4 - 4 7.8 
Postauricular  2 1 3 5.8 
Neck  - 3 3 5.8 
The central region of the face namely the nose, cheek region, 
eyelid, perioral involvement is more commonly involved in localized 
type. 
Scalp involvement was observed in 50% cases. Thirty nine patients 
had lesions on face constituting 76%. In face cheek was found to be the 
common site seen in 39% of study group. Concha sign was seen in 35% 
of patients. 
 
  
 
         Localized DLE- 
involvement of head & neck 
     DisseminatedDLE-  
involvement of head & neck 
                     
Table 9 – Involvement of sites other than head and neck 
Site Localized Disseminated Total  % 
Upper limb - 19 19 37.25 
Trunk 4 19 23 45.09 
Lower limb 1 7 8 15.68 
Four patients (7.9%) with single to few lesions restricted to 
involvement of one region alone namely chest, lower back, gluteal region 
without head and neck lesions are included in the localized type in our 
study. One patient with only 2 lesions, on concha and the other one on 
chest was also categorized as localized type. 
  
 
Widespread involvement is more commonly noticed in 
disseminated type. The upper limb involvement was seen in 37%, trunk 
involvement in 45% and lower limb was involved in 15% of study group. 
The lesions on lower limb are encountered only in 7 patients with 
disseminated lesions. 
Table 10: Distribution of lesion in relation to sun exposure 
Type 
Sun exposed 
site 
Exposed and 
unexposed 
sites 
Un exposed 
site 
Localized  29 - 1 
Disseminated  21 13 13 
One elderly female had localized verrucous DLE only on both 
gluteal regions. 
Unexposed /covered site involvement seen in [14/51]-27.4% of 
total DLE patients 
Unexposed /covered site involvement seen in disseminated DLE- 
[13/21] -61.9% 
 
  
 
Table 11: Total No of lesions 
Type  <5 5-9 >10 
Localized 20 10 - 
Disseminated  2 4 15 
Localized disease was classified as mild (<5), moderate (5-9) and 
severe (>10) depending on the total no. of lesions 
Twenty among thirty patients (66%) had mild localized disease and 
10 patients (33%) had moderate form of localized disease. None of the 
patient had severe form of localized disease. 
 
 
 
 
 
 
 
  
 
Table 12: Mucosal pattern of involvement 
Morphology Upper lip 
 
Lower 
lip 
Buccal 
mucosa 
Palate Gingiva 
Discoid 10 20 - - - 
Erythematous 
plaque 
-  1 - - 
Depigmented / 
white patches 
- - 2 1 2 
Ulcerated 
plaque / 
cheilitis 
- 1 - - - 
Erosion - - - 2 - 
Total 10 21 3 3 2 
Classical discoid lesions are the most common mucosal pattern. 49% of 
the study group had mucosal lesion. 
 
 
 
  
 
Table No 13: Site of mucosal involvement 
Mucosal site No. of  patients Percentage % 
Upper lip 10 40 
Lower lip 21 84 
Buccal mucosa 3 12 
Palate 3 12 
Gingiva 2 8 
Lower lip was the commonest site involved in oral mucosa in our 
study observed in about 84% (21 of 25). The next common site being 
upper lip involved in 40%. Nine patients (36%) had involvement of both 
upper and lower lip. 
 
 
 
 
 
  
 
Table No 14: Pattern of mucosal involvement 
Pattern  No. of patients Percentage % 
Discoid  21 84 
Erythematous plaque 1 4 
Depigmented / white 
patches 
2 8 
Ulcerated plaque / 
cheilitis 
1 4 
Erosion  2 8 
The discoid lesion was observed in 84% of patients with mucosal 
involvement. Depigmented white patches were seen in 2 patients (8%). 
Cheilitis and erythematous plaque were observed in 1 patient each i.e.4%. 
Palatal erosion was seen in 2 patients (8%). 
 
 
 
 
  
 
Table 15: Alopecia in DLE 
Type Scalp lesion 
Disfiguring 
Scarring 
alopecia 
Diffuse 
nonscarring 
alopecia 
Localized  11 10 - 
Disseminated          15 10 3 
Twenty six patients had scalp lesions constituting 50% of study 
group. Twenty out of twenty six patients (76%) had disfiguring scarring 
alopecia.  Six patients (23%) only had few small lesions over scalp with 
out much disfiguring scarring alopecia. Three patients with disseminated 
DLE had diffuse non scarring alopecia. 
The Systemic Lupus International Collaborating Clinics (SLICC) 
group revised and validated the American College of Rheumatology 
(ACR) systemic lupus erythematosus (SLE) classification criteria in 
which they have included non scarring alopecia as one of the clinical 
criteria. Though all 3 patients with diffuse non scarring alopecia has not 
satisfied ARA criteria during the study period, follow-up is required and 
advised in all of them. 
  
 
Anti Nuclear antibodies: 
ANA was done in 30 patients, by FANA method in 15 patients and 
in another 15 by ELISA method. 7 among localized type and 15 among 
disseminated type showed ANA positivity. The granular/speckled pattern 
is the most common pattern observed by FANA method in our study. 
73% (22/30) showed ANA positivity. 
Table 16: ANA in DLE 
ANA 
Positive 
Localized 
Positive 
Disseminated 
Negative 
Localized 
Negative 
Disseminated 
ELISA 3 6 6 0 
IFA 4 9 1 1 
Table 17: Pattern in ANA by IFA 
Pattern –ANA(IFA) 
No of patients 
Localized    Disseminated 
Granular /Speckled 3 5 
Homogenous - 3 
Nucleolar 1 - 
Nuclear dots - 1 
 
  
 
Table 18: Histopathological findings 
Histopathological findings 
No. of 
Patients 
Hyperkeratosis  47 
Follicular plugging  46 
Epidermal thinning 46 
Basal layer degeneration (focal to diffuse) 51 
Pigment incontinence 25 
Subepidermal bulla 3 
Inflammatory infiltrate Lymphocytic in upper dermis 48 
Periappendageal  49 
Perivascular  46 
Interstitial  33 
Pilosebaceous atrophy 15 
Mucin deposition 5 
Mixed Panniculitis 2 
Carcinomatous changes- Horn pearls & individual cell 
keratinization 
2 
HPE showed classical features of DLE in all cases. Tumid lesions 
showed focal basal layer degeneration, perivascular, periappendageal 
inflammatory infiltrate with no epidermal changes. Mucosal lesion 
  
 
showed features of basal layer degeneration with inflammatory infiltrate 
in the upper dermis and in perivascular region. 2 patients (3.9%) showed 
features of malignancy on clinico-pathological correlation. 
Direct immunofluorescence: 
Two cases with disseminated lesion showed deposits in both 
lesional and covered region. 1case of disseminated DLE showed no 
deposit both in lesional and covered region possibly due to treatment 
Table 19: Direct immunofluorescence findings 
Clinical 
picture 
Deposits Site  1.Lesional 
2.Nonsunexposed, 
Uninvolved 
Comment  
LEP IgG,IgM, 
Fibrinogen 
Septae 
of fat 
1 LEP 
LDLE Ig G-band BMZ 1 DLE 
DDLE IgG,IgA, 
fibrinogen 
BMZ 1 LBT+ 
IgG,IgA BMZ 2 
DDLE IgM,IgA,C3 BMZ 1 LBT+ 
IgM BMZ 2 
DDLE No deposits BMZ 1, 2 On 
treatment 
LDLE—Localized DLE     BMZ—Basement Membrane Zone 
DDLE—Disseminated DLE   LBT—Lupus Band Test LEP – LE  panniculitis 
  
 
Associations of DLE: 
Twelve patients (23.5%) who satisfied ARA criteria had anti ds-DNA 
positivity. 13% (7/51) showed features of thyroid dysfunction in our 
study. One patient developed DLE lesions over herpes zoster site. 
Table 20: Other LE features associated with DLE       
   Other LE features No. of patients Percentage 
% 
Photosensitivity 42 
 
82 
Malar rash 2 
 
3.9 
SCLE 2 
 
3.9 
Oral ulcer 2 
 
3.9 
Arthralgia 20 
 
39 
Telangiectasia 1 
 
1.9 
Anaemia 8 
 
15.6 
Proteinuria 3 
 
5.8 
Lupus nephritis 1 
 
1.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 21:  Cutaneous associations of DLE       
Cutaneous associations No.of patients 
 
Percentage % 
 
PLE 1 1.9 
Melasma 2 3.9 
Macular amyloid 1 1.9 
Herpes zoster 2 3.9 
Leprosy 2 3.9 
Vitiligo 1 1.9 
 
 
Table 22:  Systemic associations of DLE 
 
Systemic associations No. of patients Percentage % 
SLE 12 
 
23.5 
Systemic sclerosis 1 
 
1.9 
Thyroid dysfunction 7 
 
13.7 
 
Complications:   
1.Ulceration was observed in 2 patients on DLE lesions on lower limbs. 
Similarily ulceration was observed in LE  panniculitis.  
2. Squamous cell carcinoma over DLE lesion on arm and elbow 
respectively was observed in 2 patients with disseminated DLE.  
  
 
DISCUSSION 
Incidence: 
In our study, the incidence of DLE was 0.47 per 1000 cases (51 
among 106368 new cases) among patients attending the skin OPD during 
the period from October 2010 –September 2012. The incidence of DLE in 
one study was 3.56 per 100 000 persons. 
[8] 
Age distribution: 
The age of the patients ranged from 15 to 70 years. The mean age 
at onset of the disease is 38.56 when compared to 36 and 31.4 years in 
other studies 
[120] [136]
. The majority of the patients (19 patients or 37.25%) 
fall in the age group from 31-40 years. 30 of 51 patients or 58.81% of 
patients in this study fall in the age group from 21-40 years as against 
78% in the study
 
done by Bajaj et al
[136]
. 
Sex distribution: 
Female to male ratio in our study is 4.1:1. Several studies show 
female predominance ranging from 2:1 to 5:1
[117,118,119,120]
 .The female to 
male ratio in localized type is 9:1 and in disseminated type it is 2:1. 
Localized type was observed more common among female patients. 
Among male patients disseminated type (7 of 10) was found in higher 
  
 
proportion in our study. Equal ratio and male predominance was reported 
in few studies. 
[137,138]
 
Familial incidence: 
Family history of SLE with ACLE rash was seen in a daughter of 
the male patient with DDLE. Familial discoid lupus erythematosus 
among siblings have been reported in the literature 
[144,145]
. Family history 
of SLE has been reported among 2 DLE patients in a study 
[120]
. 
Inducing Factors:  
UV exposure, viral infection, drugs and smoking reported as 
inducing factors of lupus erythematosus in the literature was also 
observed in our patients were in concordance.
[17,18,20,28,29,30] 
CLINICAL FEATURES: 
Types of DLE: 
Localized DLE was found in 30 patients (58.82%), Disseminated 
DLE in 21 patients (41.17%) similar to the study by Insawang et al 
[120]
 
Localized type of DLE was the commonest type in our study 
(58.82%). Five patients among thirty (16%) presented with single to few 
  
 
lesions on sites other than head and neck were classified as localized type 
in our study. 
Total No. of lesions: 
Localized disease was classified into mild (number of lesions less 
than 5), moderate (5-9 lesions) and severe (more than 10 lesions) by Bajaj 
et al
[136]
 depending on the number of the lesions. 20(66%) patients had 
mild localized disease, 10 (33%) patients had moderate localized disease 
in our study. 
Distribution of skin lesions: 
Face (76%) was the most commonly involved site which is in 
concordance with other studies done by Callen et al, Insawang et al. 
[119,120]
 followed by scalp(50%). Ear involvement in the form of concha 
sign or Shuster‘s sign was seen in 35% in our study. Shuster‘s sign occurs 
in up to 1/3
rd
 [33%] of cases of DLE 
[49]
. 
Scalp involvement was seen in 50% in our study, it was 40% in the 
study by Sandipan et al. Forehead lesions were seen in 25% in our study 
where as it was 65% in the Sandipan et al study. Nasal lesions were seen 
in 76% in Sandipan et al study it was lower 29% in our study. Cheek 
involvement was seen in 39% in our study, it was higher 78% in 
  
 
Sandipan et al study. Lesions on trunk were seen in 45% in our study it 
was 27% in Sandipan et al study. Arms and forearms involvement were 
observed in 37% in our study it was 19% in the study by Sandipan et al. 
Lower limb involvement was seen in 15% in our study which is similar 
11% in the Sandipan et al study. Involvement of forehead, nose, cheek 
and concha were lower in our study when compared to Sandipan et al. 
study. The trunk and upper limb involvement were higher in our study 
when compared to Sandipan et al. study. 
The most of the patients had lesions on sun exposed region 
[50/51]-98%. The Unexposed /covered site involvement was seen in 
[14/51]-27.4% of both localized and disseminated DLE patients. The 
Unexposed /covered site involvement seen in disseminated DLE was 
[13/21] -61.9%. 
Eye changes: 
 Eyelid discoid lesion, blepharitis, conjunctivitis, proptosis, 
periorital edema that have been observed in our study have been reported 
in literature 
[85-94]  
 
 
  
 
Palms and soles involvement: 
Two male and 1 female with disseminated DLE had palmoplantar 
lesions constituting 5.8% in our study. Verrucous lesions and ulceration 
of DLE lesion over legs was observed in patients with palmoplantar 
involvement.  
Thus palmoplantar involvement is quite rare ranging from 0.98% 
to 2.27% in other studies 
[139,140] 
Variants: 
Mucosal DLE: 
The lower lip (84%) was the most common site involved in the oral 
mucosa, discoid lesion (84%) involving the exposed part of lip was the 
most common pattern of involvement in our study. The buccal mucosa, 
palate and vermilion of lips (more the lower than the upper lip) are 
referred as the commonest sites for lupus oral lesions. 
[74,146,147,148]
 
Sandipan et al in their study reported oral mucosal involvement in 7.84% 
and lip lesions in 31% 
[140]
, in our study mucosal manifestation was 
observed in 49% of patients. Both upper and lower lips were involved in 
9 patients of 25 with mucosal involvement (36%).  
  
 
The other oral manifestations were erythematous plaque (involving 
lowerlip and buccalmucosa), depigmented patches/white squamous 
(involving buccal mucosa, palate and gingival), cheilitis and palatal 
erosion in our study. 2 patients (3.9%) with palatal erosion had features of 
SLE. 
The clinical aspects of mucosal lesions described in LE patients in 
the study by Lourencxo et al. were erythemato-squamous plaque, 
erythemato-atrophic plaque, erythemato-ulcerative plaque, squamous-
discoid, atrophic-discoid, cicatricial-discoid, ulcerative, keratotic, 
purpuric, bullous, white-squamous, atrophic, hyperchromic etc
 [74] 
Mucosal involvement was seen in 12 patients of localized disease 
and 13 patients of disseminated disease. 
Verrucous or hypertrophic DLE: 
In our study 4 patients (7.8%) had verrucous DLE which is higher 
when compared to the study by Insawang et al. i.e. 1.5% 
[120]
 
Lupus Panniculitis: 
Erythematous tender sharply demarcated plaque over the forehead 
extending to scalp, with few tender plaque and nodules over mandibular 
region, proximal arms was the presentation in 1 patient. Two patients 
  
 
(3.9%) had LE panniculitis in our study which was lower when compared 
to the study by Bajaj et al (9.1%) 
[136]
. But was higher when compared to 
Insawang et al study, they reported LE panniculitis in 2.3% 
[120]
 
Tumid LE: 
Two patients (3.9%) presented with tumid lesions over face.  Bajaj 
et al. in his study reported tumid lesions in 18.2% of patients 
[136]
, but 
only 3.9% showed tumid lesions in our study. Tumid LE was reported in 
0.8% in the study by Insawang et al. 
[120]
 
The site involved in our patients with tumid LE namely the nose 
and malar region (sun exposed region) is in concordance with the other 
studies 
[67]    
Alopecia in DLE: 
The patients with scalp lesions were 26(50.9%). Disfiguring 
scarring alopecia was found in 20 patients (39.21%) in our study, nearly 
similar (34%) to a study done by Wilson et al. 
[141]
 Diffuse hair loss was 
observed in 3 patients. The Systemic Lupus International Collaborating 
Clinics (SLICC) group revised and validated the American College of 
Rheumatology (ACR) systemic lupus erythematosus (SLE) classification 
criteria in which they have included non scarring alopecia as one of the 
  
 
clinical criteria. 
[131]
 All 3 patients with diffuse non scarring alopecia 
during the study period have not satisfied ARA criteria, hence follow-up 
is advised in all of them. 
Associations: 
Course of DLE and its association with SLE: 
In our study 3 patients of localized disease (5.8%) and 9(17.6%) 
with disseminated disease satisfied ARA criteria for SLE. The specific 
anti ds-DNA was positive in all patients who satisfied ARA criteria. 
According to literature nearly 5 percent of patients with isolated localized 
DLE subsequently develop SLE 
[9]
 and the risk is higher in patients with 
disseminated DLE (22%) 
[11]
. Renal and hematological abnormalities 
were commonly involved in our study.  Immunological tests ( ANA, DIF) 
were not done in all the patients and are the limitation in our study.   
       Photosensitivity was present in 42 patients (82.3%). 
Photosensitivity was reported less among DLE patients when compared 
to SCLE, ACLE 
[118]
. Photosensitivity was seen in 14.6% to 87% in 
various other studies of DLE patients. 
[118,119]
 
 Arthralgia was present in 20 patients (39.2%) in our study 
compared to 47% in the study by Bajaj et al 
[136]
.  
  
 
Malar rash was observed in 2 patients (3.9%) where as it was 
16.2% in the study by Insawang et al.
 [120]
 Psoriasiform SCLE rash was 
seen in a patient with SLE along with few discoid lesions. In our study 2 
patients (3.9%) had SCLE lesion which was 2.3% in the study by 
Insawang et al
 [120] 
Oral ulcer was seen in 2 patients (3.9%) in our study, it was 13% in 
Insawang et al study 
[120]
. Proteinuria was present in 3 patients (5.8%), in 
the other study it was 11.5% 
[120]
. Established lupus nephritis was 
observed in 1 among the patients with albuminuria. Facial telangiectasia 
was observed in 1 patient (1.9%).
 
Other systemic associations were systemic sclerosis, thyroid 
dysfunction (in the form of auto immune thyroiditis, hypothyroidism, 
hyperthyroidism and goiter). The association with systemic sclerosis, 
[106]
 
thyroiditis
[101] 
 have been reported in literature. 13% showed thyroid 
dysfunction in our study. 
Cutaneous associations observed were PLE 
[102,103,104]
 in 1 patient, 
Hansen‘s disease in 2 patients and one had deformity, melasma in 2 
patients and macular amyloid on lower limbs in 1 patient with scalp DLE. 
Vitiligo was observed in 1 patient with disseminated DLE. 
  
 
The association of DLE with PLE 
[102,103,104] 
vitiligo
[105] 
and primary 
localized cutaneous amyloidosis in lupus erythematosus 
[142]
 have been 
previously reported in literature. The pathogenesis in LE and leprosy was 
attributed towards marked decrease of CR1/E (complement receptor in 
erythrocytes), which may result in an altered clearance of elevated 
immune complexes 
[143] 
Other coexisted condition was herpes zoster in 2 patients (3.9%). 
Histopathology: 
The classical histopathological findings were seen in all the cases 
of DLE and its variants. The most significant histological finding basal 
layer degeneration focal to diffuse was observed in 100%. Hyperkeratosis 
(92%), follicular plugging (90%), epidermal thinning (90%), pigment 
incontinence (49%), upper dermal lymphocytic infiltrate (94%), 
periappendageal (96%) and perivascular infiltrate (90%), interstitial 
infiltrate (64%), pilosebaceous atrophy (29%) was observed. Sub 
epidermal bulla was observed in the biopsy of 3 patients (5.8%) 
particularly from specimen over scalp lesions. Mucin deposition in the 
dermis was less observed in H&E section, seen only in 5 patients (9.8%). 
Histological diagnosis concurred with clinical diagnosis in 100% in the 
study conducted by David-Bajar et al 
[150]
 which is similar in our study. 
  
 
Features of squamous cell carcinoma were seen in the biopsy of 
verrucous growth seen on DLE lesion from 2 patients (3.9%).  
Anti nuclear antibodies: 
ANA was done by ELISA method in 15 patients and by IFA 
(indirect fluorescent antibody) method in 15 patients. 22 of 30 patients 
(73%) showed ANA positivity in our study, compared to 68.5% in 
Insawang et al study 
[120] 
Of 15 patients, 13 showed positive reaction by IFA method. The 
speckled /granular pattern was the most common pattern in our study 
seen in 8 of 13 (61%), followed by homogenous pattern in 3 of 13(23%). 
Nucleolar and nuclear dots pattern were observed in each patient 
respectively. The homogenous pattern was reported twice frequent as 
speckled pattern in other studies in LE. The speckled pattern that was 
observed frequently in our study was similar to the study by Insawang et 
al 
[120].
 
 Based on staining intensity scaling was given from 1+ to 4+. 
Strong reaction was indicated as 4+, weak reaction by 1+. The staining 
intensity of more than 1+ was observed in 5 patients. 3 among these 5 
patients showed other features of SLE. 
  
 
Direct immunofluorescence: 
DIF was done for 5 patients. Among the 3 patients with 
disseminated disease, 2 showed positive lupus band test and no deposits 
was found in 1 patient(possibly due to prior treatment). In lupus 
panniculitis, the deposits of IgG, IgM, fibrinogen was seen in septae of 
fat. The deposits of immunoreactants were found in lesional skin in 
localized disease in 1 patient. 
Other laboratory and clinical parameters: 
Elevated ESR more than 50 mm/hr was observed in 6 patients 
(11.7%) which was lower (30.39%) when compared to the study done by 
Sandipan et al 
[140]
. Lymphadenopathy was found in 2 patients (3.9%) 
with disseminated DLE. 
Complications and sequlae: 
Two patients (3.9%) with disseminated disease developed 
squamous cell carcinoma on lesions over exposed sites such as lower 
back, elbow and arm respectively. Malignant change was observed in 1 
male and in 1 female. The duration of the DLE lesion in both patients was 
4 and 13years respectively. Thus 3.9% of DLE patients in our study 
  
 
showed malignant change. Squamous cell carcinoma was reported in 1 
patient in the study done by Sandipan et al
[140]
 
Ulceration over DLE lesion was observed in leg lesions and over 
panniculitis plaque totally in about 3 patients (5.8%). 
Scarring was observed in 18 patients (35%), pigmentary alterations 
in 8 patients (15%) in our study.  
Interesting observation: 
One patient with disseminated DLE developed herpes zoster in 
thoracic segment. After resolution of zoster she developed DLE lesion 
over the healed scar. The histopathological findings showed features 
consistent with DLE. Similar observation has been reported as 
isomorphic phenomenon though there was confusion in labeling it as 
isomorphic or isotopic phenomenon 
[149,135]
 
 
 
 
 
  
 
SUMMARY 
Incidence  
DLE constituted 0.47 per 1000 of the total patients attending the 
skin OPD during the study period.  
Age 
The age of the patients ranged from 15 to 70 years. 58.81% of 
patients were between 21-40 years of age. 
Sex: 
Female to male ratio in our study was 4.1:1. 
Familial involvement: 
Family history of SLE was observed in an offspring of male patient 
with disseminated lesions. 
Clinical features: 
Localized type constitutes 58.82%, disseminated type constitutes 
41.17%. The variants observed in our study were mucosal DLE, 
verrucous DLE, LE panniculitis and tumid LE. Classical discoid lesion 
was present in 94% cases. Mucosal involvement was seen in 49%. 
  
 
Hypertrophic DLE lesion, LE panniculitis, tumid LE was found in 7.9%, 
3.8% and 3.8% respectively. There was significant overlap in the 
morphological variants studied. 
Face was the most common site involved 76% followed by the 
scalp in 50%. Concha sign was found in 35%. 
The lower lip was the most common site involved in the mucosa 
with discoid lesion being the most common pattern. 
Verrucous lesions were commonly observed in elbows and knees. 
Tumid lesions were seen in the nose and malar region of the face. 
Panniculitis involved the face and the extremities in both the cases. 
Scarring alopecia was observed in 39.21%. 
Ocular involvement was in the form of discoid lesion in the lower 
eyelid with blepharitis and conjunctivitis. Proptosis and periorbital edema 
was also observed. 
Palmo plantar involvement was noticed in 5.8%. 
 
 
  
 
Histopathology:  
HPE findings were consistent with the diagnosis in all cases in 
whom biopsy was done. Focal to diffuse basal layer degeneration was 
seen in all the patients studied (100%).  
ANA test: 
23 of 30 patients showed positivity. The speckled/granular pattern 
was the most common pattern in IFA method in our study. The staining 
intensity of more than 1+ was observed in 5 patients. 
Direct immunofluorescence: 
DIF was done for 5 patients. 2 of them showed positive lupus band 
test. 
Associations: 
5.8% of localized disease and 17.6% with disseminated disease 
satisfied ARA criteria for SLE and showed antids-DNA positivity. 
Other systemic associations were systemic sclerosis, thyroid 
dysfunction (in the form of thyroiditis, hypothyroidism, hyperthyroidism 
and goiter). 
  
 
Cutaneous associations observed were PLE, Hansen‘s disease, 
melasma, macular amyloid and vitiligo. 
Neoplasm: 
Two patients with disseminated disease developed squamous cell 
carcinoma on lesions over exposed sites. 
 
 
 
 
 
 
 
 
 
           
  
 
CONCLUSION 
 A total of 51 patients had DLE lesions during the study period with 
an incidence of 0.47 per 1000 cases attending dermatology OPD. The 
majority of our patients had disease onset at 3
rd
 and 4
th
 decade. Females 
outnumbered males in our study. Among male patients disseminated type 
was found more frequent than localized type. The distribution of lesion 
inferred that the majority of patient with lowerlimb and palms & soles 
involvement had complications like ulceration. 5.8 % of localized type 
and 17.6 % of disseminated type had SLE during the study period. But 
serious morbidity like lupus nephritis was observed in only one patient 
implying the benign nature of DLE. Cutaneous and systemic associations 
observed in our study were PLE, Hansen‘s disease, melasma, macular 
amyloid, vitiligo, systemic sclerosis and thyroid dysfunction. Squamous 
cell carcinoma was observed in two patients with disseminated lesion. 
Another interesting observation made was development of DLE lesion 
over herpes zoster site, an isomorphic phenomenon.  
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            A clinical study on  DISCOID LUPUS  ERYTHEMATOSUS 
 
                                                PROFORMA                          
 
Case no:                                                                                      Date: 
 
NAME AGE SEX 
 
ADDRESS                                     ph no:                                            
occupation:  farmer, Construction worker, Others 
AGE  AT  ONSET OF LESION 
DURATION OF LESION 
H/O PHOTOSENSTIVITY 
H/O ORAL LESION 
SYSTEMIC SYMPTOMS 
 H/O Raynaud‘s phenomenon , joint pain , dyspnoea , muscle weakness, 
chest pain, dysphagia, oliguria, visual disturbances, seizures, hair 
loss,menstrual disturbances,spontaneous or recurrent abortion 
TRIGGERING FACTORS 
 H/O drug intake  
                                                                                                                    
 H/O fever,preceeding infection                                                                                               
  
 
 H/O vaccination 
 H/O UV exposure 
 H/O trauma 
 H/O  X-Ray Exposure                                                                                                                                                                                                                                                               
 H/O seasonal variation  
 H/O smoking                                                                                                                            
FAMILY H/O: 
TYPE-LOCALISED,               DISSEMINATED 
 
MORPHOLOGY 
1. Classic discoid LE (DLE) 
a. Localized DLE 
b. Generalized DLE 
2. Hypertrophic/verrucous DLE 
3. Lupus profundus/lupus panniculitis 
4. Mucosal DLE 
5. Lupus tumidus (urticarial plaque of LE) 
6. Chilblain LE (chilblain lupus) 
7. Lichenoid DLE (LE/lichen planus overlap, lupus 
planus) 
NUMBER OF LESION:   < 5           5-10        >10 
  
 
SITE& NO:1.head&neck                                                                                                                
Scalp                                                                                                                                           
Face-forehead            Nose                      Ear –concha,            triangular 
fossa                                                                                                                                                             
cheek               perioral                         lids 
2.Disseminated-exposed,        unexposed,       both 
  Trunk,     upper limbs,     lower limbs,      palms & soles 
NON SPECIFIC LE LESION 
 
 MUCOSA- site, pattern  
 HAIR- 
 
SEQULAE 
scarring 
pigmentation 
cribriform perioral scar 
calcification 
 
 
 
  
 
COMPLICATION 
 
NEOPLASM-SCC 
 
INVESTIGATIONS      
COMPLETE HEMOGRAM 
URINE ANALYSIS 
RFT 
LFT 
ANA 
HPE 
 
DIF                      
                                                      
 OTHER  DISEASE ASSOCIATIONS 
PLE,      thyroiditis -hypo/hyper ,    Porphyria,       pemphigus,    
Polychondritis,        vitiligo,       others. 
 
Risk factors for the development of SLE in patients with DLE: 
CLINICAL- 
 Generalized lymphadenopathy; 
 SCLE/ACLE skin lesions; 
  
 
 LE-non-specific skin lesions such as vasculitis, 
 Diffuse non-scarring alopecia, 
 Periungual nail fold telangiectasia,  
 Raynaud phenomenon; 
LAB-  
Unexplained anemia; 
Marked leukopenia; 
False-positive tests for syphilis;  
ANA positivity; 
Hypergamma-globulinemia; 
ESR (especially > 50 mm/hour);  
positive, sun-protected, non-lesional lupus band test (LBT) . 
 
 
 
, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
KEY TO MASTER CHART 
A  - Anaemia 
AHT - Antipsychiatry drugs 
ATT -  Anti tuberculous drugs 
Alb - albuminuria 
Bm - Buccal mucosa 
C  - Classical discoid lesion 
     D  - Disseminated 
DP -  depigmented patch 
DNSA - diffuse non scarring alopecia 
Dis - discoid 
E  - Erosion 
EP  - erythematous plaque 
F  - Female 
Gin - gingiva 
HZ - Herpes zoster 
L  - Localized 
LN -  lupus nephritis 
Lp  - Lower lip 
M  - Male 
Mu - Mucosa 
MA - Macular amyloid 
Ma.r - Malar rash 
Mel - melasma 
Neg - negative 
OE - oral erosion 
P  - present 
Pa  - Panniculitis 
  
 
Pal - Palate 
Pos - positive 
S  - satisfied 
SA - scarring alopecia 
SSc - Systemic Sclerosis 
Sm - smoking 
T  - telangiecctasia 
TD - thyroid dysfunction 
Thy - thyroxine 
Tr  - trauma 
Tu  - Tumid DLE 
V  - Verrucous DLE 
Vo - Vitiligo 
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1 Maheswari 37 F 2mo - L C 3 _ _ _ P P _ _ _ _ _ _ _ _ _ Yes No _ _ _ Done _ - _ _ _ _
2 Jothibasu 40 M 6mo - L C 1 _ _ _ _ _ _ _ _ _ _ P _ _ _ Yes No _ _ _ Done Pos - _ _ _ _
3 Rajammal 43 F 9yrs - L C,Mu 1 _ _ _ _ _ _ _ _ _ _ P _ _ _ Yes No Pal E _ Done Pos - _ P A,OE S
4 Pandi 67 M 3yrs AHT, sm L C 1 _ _ _ _ P _ _ _ _ _ _ _ _ _ Yes No _ _ _ Done Neg - P _ _ _
5 Perumayee 43 F 2yrs Tr L C 2 P _ _ _ _ _ _ _ _ _ _ _ _ _ Yes No _ _ SA Done _ - P _ _ _
6 Kalidas 32 M 5yrs sm L C 4 P P _ _ _ _ _ P _ _ _ _ _ _ Yes No _ _ SA Done _ - P _ _ _
7 Sumathy 21 F 5yrs - L C 6 _ _ _ P P _ _ P _ _ _ _ _ _ Yes No _ _ _ Done _ - P _ _ _
8 Jammaal Beevi 42 F 13yrs AHT L C 6 P _ _ P P P _ P _ _ _ _ _ _ Yes No _ _ SA Done Neg - P _ _ _
9 Malathy 27 F 4mo - L C 5 _ _ _ P P P _ _ _ _ _ _ _ _ Yes No _ _ _ Done Neg - P _ _ _
10 Mariammal 55 F 5yrs AHT,Tr L C 5 P _ _ _ P _ _ _ _ _ _ _ _ _ Yes No _ _ SA Done _ - P _ T _
11 Ayyamma 26 F 5mo - L C 2 _ _ _ P P _ _ _ _ _ _ _ _ _ Yes No _ _ _ Done _ - P _ _ _
12 Usharani 39 F 1yr ATT L C 6 P _ _ _ P _ _ _ _ _ _ _ _ Yes No _ _ SA Done Pos MA P _ A S
13 Pitchaii ammal 53 F I1/2yrs ATT L C 2 _ _ _ _ _ P _ _ _ _ P _ _ _ Yes No _ _ _ Done Pos - P P _ _
14 Ramayee 59 F 1yr AHT L C 6 P _ _ _ _ _ _ _ P _ _ _ _ _ Yes No _ _ SA Done _ - P P _
15 Kamatchi 42 F 3yrs - L C 5 P _ _ _ _ _ _ P _ _ _ _ _ _ Yes No _ _ SA Done _ - P P _ _
16 Shanthi 39 F 6mo - L C 3 P P _ _ _ _ _ _ _ _ _ _ _ _ Yes No _ _ SA Done Neg H P _ _ _
17 Virumayee 38 F 12yrs - L C 1 P _ _ _ _ _ _ _ _ _ _ _ _ _ Yes No _ _ SA Done _ PLE P _ _ _
18 Shanthi 39 F 3yrs thy L C,Mu 4 P _ _ P _ _ _ _ _ _ _ _ _ _ Yes No Lp Dis _ Done _ TD _ P _ _
19 Karuppi 43 F 7yrs - L C,Mu 4 _ _ _ _ _ _ _ _ P _ _ _ _ _ Yes No Lp Dis _ Done _ - P _ _ _
20 Gulzar banu 40 F 3mo - L C,Mu 5 _ _ _ _ _ P P _ _ _ _ _ _ _ Yes No Lp Dis _ Done Neg Mel _ _ _ _
21 Gandhimathi 23 F 1mo - L C,Mu 2 _ _ _ P _ _ _ _ _ _ _ _ _ _ Yes No Lp Dis _ Done _ - P _ _ _
22 Poovandhi 39 F 1yr - L C,Mu 5 _ _ P P P _ _ _ _ _ _ _ _ _ Yes No Lp Dis _ Done Neg - P _ _ _
23 Natchi 34 F 1yr - L C,Mu 6 P P P _ _ _ P _ _ _ _ _ _ _ Yes No Up,Lp Dis SA Done Pos TD P P _ _
24 Meenatchi 22 F 1yr thy L C,Mu 4 _ _ _ P P _ _ _ _ _ _ _ _ _ Yes No Up,Lp Dis _ Done Neg TD P P _ _
25 Pitchaiammal 55 F 1mo - L C,Mu 3 _ _ _ _ _ _ _ _ _ _ P _ _ _ Yes No Lp Chei _ Done Pos TD P _ Alb S
26 Petchiammal 31 F 6mo - L C,Tu,Mu 6 _ _ _ P P P _ _ _ _ _ _ _ _ Yes No Up Dis _ Done _ - P _ _ _
27 Sakila 36 F 2yrs herpes L C,Mu 1 _ _ _ _ P _ _ _ _ _ _ _ _ _ Yes No Lp Dis _ Done _ - _ _ _ _
28 Pitchaiammal 30 F 5yrs - L C,Mu 2 _ _ _ _ _ _ P _ _ _ _ _ _ Yes No Up,Lp Dis _ Done _ - P _ _ _
29 Chellamani 47 F 2yrs - L Tu 1 _ _ _ P _ _ _ _ _ _ _ _ _ _ Yes No _ _ _ Done Pos Mel _ P _ _
30 Kuruvammal 68 F 2yrs - L V 4 _ _ _ _ _ _ _ _ _ _ _ _ P _ No Yes _ _ _ Done _ - _ _ _ _
31 Chandra 41 F 4mo - D C >10 P P _ _ P _ _ _ _ P P P _ _ Yes No _ _ _ Done _ - P _ _ _
32 Vellaiyammal 42 F 8yrs - D C 5 P _ _ _ _ P _ _ _ _ P P _ _ Yes No _ _ DNSA Done Pos SSc,Vo,TD P _ _ _
33 Sundarrajan 45 M 2yrs sm D C >10 P P _ _ _ P _ _ _ _ P P _ _ Yes Yes _ _ SA Done Pos familial P _ _ _
34 Balasubramaniam 37 M 3yrs - D C,Mu >10 P _ _ _ P P _ _ _ _ P P P _ Yes Yes Bm,gin DP SA Done Pos TD P P A S
35 Viji 27 F 2mo varicella D C >10 _ _ _ _ P P _ _ _ _ P P _ _ Yes No _ _ DNSA Done Pos - P P _ _
36 Chitra 26 F 12yrs - D C 4 P P _ _ _ _ _ _ _ _ P _ _ _ Yes Yes _ _ SA Done Pos - P P Ma.r S
37 Bothaguru 41 M 6yrs APT,sm D C,Mu >10 _ P _ P _ P _ _ _ P P P _ _ Yes No Lp Dis _ Done _ - _ _ _ _
38 Selvam 39 M 2mo sm D C,Mu 8 P _ _ P P P _ _ _ P P _ _ _ Yes No Up,Lp,Bm Dis,EP SA Done _ - P _ _ _
39 Amirtham 40 F 20yrs - D C,Mu >10 _ P _ _ P _ _ _ _ _ P P _ _ Yes No Lp Dis _ Done Pos - P _ _ _
40 Savithiri 25 F 13yrs - D C,Mu >10 P _ _ _ _ _ _ _ _ _ P P P _ Yes Yes Pal E SA Done Pos - P P A,OE S
41 Veerammal 37 F 1yr - D C,Mu >10 _ _ _ _ _ P _ _ _ _ P P _ _ Yes No Lp Dis _ Done Pos - P P SCLE _
42 Malarvizhi 37 F 4yrs ATT D C,Mu >10 _ P _ _ _ _ _ _ _ _ P P P P Yes Yes Up,Lp Dis DNSA Done Pos PT P P _ _
43 Kamala 40 F 6yrs - D C,Mu >10 P P _ _ _ P _ _ _ _ P P _ _ Yes Yes Up,Lp Dis SA Done Pos - P _ Alb S
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44 Veerakal 14 F 6mo Burns D C,Mu >10 P _ _ _ _ _ _ _ P _ P P _ _ Yes Yes Up,Lp Dis _ Done _ - P P _ _
45 Palaniyammal 41 F I yr - D C,Mu >10 P P _ _ _ P _ _ _ _ P P _ _ Yes No Up,Lp Dis _ Done Pos - P P Ma.r S
46 Pillapan 38 M 10yrs sm D C,Mu,V 8 P _ _ P P P _ _ _ _ P P _ _ Yes Yes Lp Dis SA Done Pos TD,HZ, P P SCLE,A,LN,alb S
47 Raja 42 M 4yrs sm D C,Mu,V >10 P _ _ P P _ _ _ _ _ P P P P Yes Yes Lp,Pal,Bm,gin Dis,DP SA Done Pos - P P A S
48 Jyoti 15 F 8mo Trauma D C,Pa 4 P P _ _ P P _ _ _ _ _ P _ _ Yes Yes _ _ SA Done Pos - P _ _ _
49 Palanisamy 40 M 20yrs sm D C,V >10 P _ _ _ _ P _ _ _ _ P P P P Yes Yes _ _ _ Done Pos H P P A S
50 Glory 25 F 5yrs - D C,Mu >10 P P _ _ _ _ _ _ _ _ P P P _ Yes Yes Up,Lp Dis SA Done _ - P _ A S
51 Selvi 26 F 2yrs - D Pa 8 _ _ _ _ P _ _ _ _ _ _ P P _ Yes Yes _ _ _ Done Neg - _ P _ _
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